Advertisement

Advertisement

2021 Pan Pacific Lymphoma Conference

Immunotherapy
Lymphoma

Lymphoid Malignancies: What’s Next for Antibody-Drug Conjugates?

Antibody-drug conjugates are improving outcomes of patients with lymphoma, often those who have exhausted treatment options after chimeric antigen receptor (CAR) T-cell therapy. Four available antibod...

Lymphoma

Putting Radiotherapy to Best Use With CAR T-Cell Therapy in Lymphoma

The integration of radiation therapy into chimeric antigen receptor (CAR) T-cell therapy may improve outcomes for patients with released or refractory lymphoma, according to Charles A. Enke, MD, Profe...

Lymphoma

Bispecific Antibodies Find a Place in B-Cell Lymphoma Treatment

In relapsed or refractory B-cell lymphomas, bispecific T-cell engager antibodies are finding a place in the treatment algorithm, said Christopher Flowers, MD, MS, FASCO, Professor and Chair of the Dep...

multiple myeloma

Muhamed Baljevic, MD, on Multiple Myeloma: Review of Novel Management Strategies

Muhamed Baljevic, MD, of the University of Nebraska Medical Center, reviews the outlook for treating patients with relapsed and refractory multiple myeloma, the rapidly expanding array of therapeutic ...

multiple myeloma

Muhamed Baljevic, MD, on Multiple Myeloma: Review of Novel Management Strategies

Muhamed Baljevic, MD, of the University of Nebraska Medical Center, reviews the outlook for treating patients with relapsed and refractory multiple myeloma, the rapidly expanding array of therapeutic ...

multiple myeloma

Nina Shah, MD, on Newly Diagnosed Multiple Myeloma: Novel Combination Therapies

Nina Shah, MD, of the University of California, San Francisco, discusses triplet drug combinations that are the current standard of care for transplant-eligible and -ineligible patients with multiple ...

lymphoma
immunotherapy

Steven M. Horwitz, MD, on Advanced-Stage Mycosis Fungoides and Sezary Syndrome: Update on Management Practices

Steven M. Horwitz, MD, of Memorial Sloan Kettering Cancer Center, discusses treatments for advanced mycosis fungoides and Sezary syndrome, including brentuximab vedotin and mogamulizumab, and how best...

lymphoma
immunotherapy

James O. Armitage, MD, on Advanced Hodgkin Lymphoma: Choosing Among BEACOPP, A-AVD, and Checkpoint Inhibitors

James O. Armitage, MD, of the University of Nebraska Medical Center, discusses various treatment regimens for patients with Hodgkin lymphoma, including BEACOPP, brentuximab vedotin, ABVD, A-AVD, nivol...

lymphoma

Sonali M. Smith, MD: Can CNS Prophylaxis Prevent Secondary High-Grade B-Cell Lymphomas?

Sonali M. Smith, MD, of the University of Chicago, discusses the many uncertainties in preventing secondary high-grade B-cell lymphomas, which have a poor prognosis; how to discern the patients at hig...

lymphoma
immunotherapy

Bruce D. Cheson, MD, and Stephen M. Ansell, MD, PhD, on Non-Hodgkin and Follicular Lymphomas: Integrating Non–CAR T-Based Treatments

Stephen M. Ansell, MD, PhD, of the Mayo Clinic, and Bruce D. Cheson, MD, of the Lymphoma Research Foundation, engage in a lively debate about CAR T-cell therapy, how it fits in with immunotherapy and ...

lymphoma
immunotherapy

Alison J. Moskowitz, MD, on ABVD in Hodgkin Lymphoma: Adding Brentuximab Vedotin and Checkpoint Inhibitors to Standard Treatment

Alison J. Moskowitz, MD, of Memorial Sloan Kettering Cancer Center, discusses the combination ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine), individualized approaches for treating patien...

hematologic malignancies
leukemia
immunotherapy

Alexey V. Danilov, MD, PhD, on Lymphoid Malignancies: Novel Agents Targeting BTK Inhibitor–Resistant Disease

Alexey V. Danilov, MD, PhD, of City of Hope, discusses the uses and side effects of cellular and immune therapies, including venetoclax and obinutuzumab, which may prove to be effective in treating h...

lymphoma

Jonathan W. Friedberg, MD, on Managing Indolent NHL With Oral Therapies

Jonathan W. Friedberg, MD, of the University of Rochester Medical Center, discusses treatment options for follicular lymphoma, focusing on the combination of lenalidomide and rituximab and why he uses...

lymphoma

Andrew D. Zelenetz, MD, PhD, on MRD Testing in the Management of Non-Hodgkin Lymphoma

Andrew D. Zelenetz, MD, PhD, of Memorial Sloan Kettering Cancer Center, discusses the role of minimal residual disease evaluation in the treatment of non-Hodgkin lymphoma, techniques used to predict r...

supportive care
hematologic malignancies

Jared E. Matya, PharmD, BCOP, on Supportive Therapies for Side Effects Related to Novel Oral Treatments

Jared E. Matya, PharmD, BCOP, of Nebraska Medicine, discusses oral agents and their toxicity profiles, as well as newer-generation agents that are often more selective and better tolerated. He describ...

supportive care
lymphoma

David S. Kroll, MD, on Recognizing and Treating Depression and Anxiety in Patients With Lymphoma

David S. Kroll, MD, of Brigham and Women’s Hospital, discusses the symptoms of distress in patients with lymphoma and other oncologic malignancies, risk factors for poor outcomes, and how best to appr...

hematologic malignancies
immunotherapy
global cancer care

Peihua (Peggy) Lu, MD, on CAR T-Cell Therapy: Research in China

Peihua Lu, MD, of Lu Daopei Hospital, discusses the state of research in China on CAR T-cell therapy, placing it in the context of the global development pipeline and the progress being made.

Advertisement

Advertisement



Advertisement